The content on this site is intended for healthcare professionals only
Dr Collins speaks at the 'measuring success in indolent disease' session during BSH 2017 in Brighton, UK.
Collins discusses 'What’s important to patients in a non-curative setting?'
The content available here was filmed at a Roche Products Limited promotional symposium and contains discussion of Roche medicines.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
EHA 2024: Multiple myeloma roundup
Belantamab mafodotin, pomalidomide and dexamethasone shows superior efficacy in RRMM compared to standard of care in 2nd line
More effective treatment options required for patients with MM post lenalidomide exposure
Treatment of multiple myeloma in Turkey
